{
    "clinical_study": {
        "@rank": "114420", 
        "acronym": "LAST", 
        "arm_group": [
            {
                "arm_group_label": "Endovenous laser ablation", 
                "arm_group_type": "Active Comparator", 
                "description": "Endovenous laser ablation with 940 nm bare fiber."
            }, 
            {
                "arm_group_label": "Endovenous steam ablation", 
                "arm_group_type": "Active Comparator", 
                "description": "Endovenous steam ablation with steam vein sclerosis system."
            }
        ], 
        "brief_summary": {
            "textblock": "Endovenous laser ablation is a common therapy of great saphenous vein insufficiency with a\n      very high success rate. It works by heating and thereby obliterating the vein. Steam\n      ablation is a new therapy that also works by heating and thereby obliterating the vein. The\n      hypothesis of this study is that steam ablation is as effective as laser ablation, but that\n      it results in better secondary outcomes (e.g., lower pain scores)."
        }, 
        "brief_title": "Steam Ablation Versus Endovenous Laser Ablation for the Treatment of Great Saphenous Veins", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Varicose Veins", 
            "Varicose Veins of Leg With Long Saphenous Vein Distribution"
        ], 
        "condition_browse": {
            "mesh_term": "Varicose Veins"
        }, 
        "detailed_description": {
            "textblock": "The study is a randomized clinical trial comparing two different therapies for endovenous\n      ablation of great saphenous veins. The aim of the study is to test whether the anatomical\n      success rate of Steam Ablation is not inferior to that of Endovenous laser ablation (EVLA)\n      in treatment of great saphenous vein insufficiency and compare the treatment safety, patient\n      reported outcomes and cost-effectiveness analyses between EVLA and Steam Ablation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients over 18 years old\n\n          -  Insufficiency of the GSV measured with ultrasound imaging, reflux > 0.5 s, and\n             diameter of vein > 0.5 cm\n\n          -  Symptoms of chronic venous insufficiency\n\n          -  No prior treatment of the insufficient GSV\n\n          -  Informed consent\n\n        Exclusion Criteria:\n\n          -  Acute deep or superficial vein thrombosis\n\n          -  Agenesis of deep vein system\n\n          -  Vascular malformation or syndrome\n\n          -  Post-thrombotic syndrome, occlusive type\n\n          -  Pregnancy\n\n          -  Immobility\n\n          -  Allergy to lidocaine\n\n          -  Arterial insufficiency"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "237", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02046967", 
            "org_study_id": "ErasmusMC"
        }, 
        "intervention": [
            {
                "arm_group_label": "Endovenous laser ablation", 
                "description": "Endovenous laser ablation with 940 nm Diode laser using a bare fiber for treating the Great Saphenous Vein.", 
                "intervention_name": "Endovenous laser ablation with 940 nm bare fiber", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "EVLT", 
                    "EVLA"
                ]
            }, 
            {
                "arm_group_label": "Endovenous steam ablation", 
                "description": "Endovenous steam ablation with steam vein sclerosis.", 
                "intervention_name": "Endovenous steam ablation with steam vein sclerosis system.", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "SVS", 
                    "EVSA"
                ]
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "endovenous laser ablation", 
            "endovenous steam ablation", 
            "great saphenous veins", 
            "quality of life"
        ], 
        "lastchanged_date": "January 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rotterdam", 
                    "country": "Netherlands", 
                    "zip": "3015 CA"
                }, 
                "name": "Erasmus MC"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparative Randomized Clinical Trial of Steam Ablation Versus Endovenous Laser Ablation for the Treatment of Great Saphenous Veins", 
        "overall_official": {
            "affiliation": "Erasmus Medical Center", 
            "last_name": "Renate R van den Bos, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands: Medical Ethics Review Committee (METC)", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Obliteration of varicose vein and/ or absence of reflux (>0.5 sec. of retrograde flow over >10cm) along the treated segment of the great saphenous vein (GSV) at 12 and 52 weeks.", 
            "safety_issue": "No", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02046967"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Erasmus Medical Center", 
            "investigator_full_name": "RR van den Bos", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Major complications: deep and superficial venous thrombosis (embolic events), nerve injury, skin burns, and (sub)cutaneous infections.", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Minor complications: ecchymosis, pain and hyperpigmentation.", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Health related quality of life will be measured using the Dutch Translated Aberdeen Varicose Vein Questionnaire (AVVQ).", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Treatment satisfaction", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Pain score", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Venous Clinical Severity Score (VCSS)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Erasmus Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Erasmus Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}